Pacific Bio (PACB) Reports In-Line Q1 EPS, Achieves Second Development Milestone
Get Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q1 EPS of ($0.27), in-line with the analyst estimate of ($0.27).
Pacific Biosciences of California, Inc. (Nasdaq: PACB), provider of the PacBio® RS II Sequencing System, today announced that it has achieved a second development milestone under its development, commercialization and license agreement with F. Hoffman-La Roche Ltd (Roche), earning an additional $10 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pacific Biosciences of California (PACB) PT Lowered to $8 at Scotiabank
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Lakeland Bancorp (LBAI) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!